Sugi Predict

Sugi Predict / Compounds / SCHEMBL4297767

SCHEMBL4297767

SCHEMBL4297767

COc1cc(/C=C/CCCC/C=C/c2ccc(NC(C)=O)cc2)c2ccccc2c1OC

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HDAC1 Q13547 1/20 0.43
▸ MAPT P10636 6/20 0.43
▸ MEN1 O00255 4/20 0.42
▸ KMT2A Q03164 4/20 0.42
▸ HPGD P15428 4/20 0.42
▸ LMNA P02545 1/20 0.42
▸ GLA P06280 1/20 0.42
▸ POLB P06746 1/20 0.42
▸ BRAF P15056 1/20 0.41
▸ ALDH1A1 P00352 2/20 0.41
▸ BCHE P06276 1/20 0.40
▸ KDM4E B2RXH2 1/20 0.40
▸ CYP1A2 P05177 1/20 0.40
▸ CYP2C9 P11712 1/20 0.40
▸ IDO1 P14902 1/20 0.40
▸ SMN1; SMN2 Q16637 2/20 0.40
▸ MAPK1 P28482 2/20 0.40
▸ GAA P10253 1/20 0.40
▸ NPC1 O15118 1/20 0.40
▸ RAB9A P51151 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13624922 1.00 HDAC1 (0.43) HDAC1MAPTMEN1KMT2AHPGD
SCHEMBL4297772 1.00 HDAC1 (0.43) HDAC1MAPTMEN1KMT2AHPGD
SCHEMBL28802494 0.73 TUBB4A (0.63) MAPTMEN1KMT2AHPGDLMNA
SCHEMBL4291294 0.71 MAPT (0.47) HDAC1MAPTMEN1KMT2AALDH1A1
SCHEMBL13624924 0.71 MAPT (0.47) HDAC1MAPTMEN1KMT2AALDH1A1
SCHEMBL4291297 0.71 MAPT (0.47) HDAC1MAPTMEN1KMT2AALDH1A1
SCHEMBL4289539 0.70 MAPT (0.46) MAPTMEN1KMT2AHPGDLMNA
SCHEMBL13624918 0.70 MAPT (0.46) HDAC1MAPTMEN1KMT2AHPGD
SCHEMBL4293602 0.70 MAPT (0.46) HDAC1MAPTMEN1KMT2AHPGD
SCHEMBL4293600 0.70 MAPT (0.46) HDAC1MAPTMEN1KMT2AHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090275664-A1 NOVEL POLYAMINE ANALOG CONJUGATES AND QUINONE CONJUGATES AS THERAPIES FOR CANCERS AND PROSTATE DISEASES PROGEN PHARMACEUTICALS, INC. 2009-11-05 — — US disclosed
US-20080194697-A1 NOVEL POLYAMINE ANALOG CONJUGATES AND QUINONE CONJUGATES AS THERAPIES FOR CANCERS AND PROSTATE DISEASES CELLGATE, INC. 2008-08-14 — — US disclosed
US-7279502-B2 Polyamine analog conjugates and quinone conjugates as therapies for cancers and prostate diseases CELLGATE, INC. (US) 2007-10-09 — — US disclosed
US-7253207-B2 Quinones as disease therapies CELLGATE, INC. (US) 2007-08-07 — — US disclosed
US-20050233943-A1 Novel polyamine analog conjugates and quinone conjugates as therapies for cancers and prostate diseases CELLGATE, INC. 2005-10-20 — — US disclosed
EP-1574507-A2 Furo- and pyrano-naphthoquinones and their use in the treatment of cancer SLIL Biomedical Corporation (US) 2005-09-14 — — EP disclosed
EP-1185493-B1 QUINONES FOR TREATMENT OF DISEASES SLIL BIOMEDICAL CORP (US) 2005-07-20 — — EP disclosed
US-20050010060-A1 Novel quinones as disease therapies SLIL BIOMEDICAL CORPORATION (US) 2005-01-13 — — US disclosed
US-6809176-B2 Quinones as disease therapies SLIL BIOMEDICAL, CORPORATION 2004-10-26 — — US disclosed
US-20040006049-A1 Novel polyamine analog conjugates and quinone conjugates as therapies for cancers and prostate diseases SLIL BIOMEDICAL CORPORATION (US) 2004-01-08 — — US disclosed
US-6649587-B1 Cytostatic or cytocidal componenet conjugated to a polypeptide recognized and cleaved by enzymes such as prostate specific antigen (PSA) and cathepsin B SLIL BIOMEDICAL CORPORATION 2003-11-18 — — US disclosed
US-20030013677-A1 QUINONES AS DISEASE THERAPIES CELLGATE, INC. 2003-01-16 — — US disclosed
US-20020183512-A1 Novel quinones as disease therapies SLIL BIOMEDICAL CORPORATION 2002-12-05 — — US disclosed
US-6482943-B1 Quinones as disease therapies SLIL BIOMEDICAL CORPORATION 2002-11-19 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050010060-A1 Novel quinones as disease therapies NQO1, NDUFV2, SDHB HDAC1 702/4885MAPT 2177/4885MEN1 909/4885
US-20040006049-A1 Novel polyamine analog conjugates and quinone conjugates as therapies for cancers and prostate diseases CTSB, CTSL, CTSV HDAC1 1497/4885MAPT 3032/4885MEN1 894/4885
US-20030013677-A1 QUINONES AS DISEASE THERAPIES NQO1, NDUFV2, SDHB HDAC1 762/4885MAPT 1738/4885MEN1 856/4885
US-20080194697-A1 NOVEL POLYAMINE ANALOG CONJUGATES AND QUINONE CONJUGATES AS THERAPIES FOR CANCERS AND PROSTATE DISEASES CTSB, KLK3, FOLH1 HDAC1 764/4885MAPT 2473/4885MEN1 524/4885
US-20050233943-A1 Novel polyamine analog conjugates and quinone conjugates as therapies for cancers and prostate diseases CTSB, CTSL, CTSV HDAC1 1497/4885MAPT 3032/4885MEN1 894/4885
US-20020183512-A1 Novel quinones as disease therapies NQO1, NDUFV2, SDHB HDAC1 702/4885MAPT 2177/4885MEN1 909/4885
US-20090275664-A1 NOVEL POLYAMINE ANALOG CONJUGATES AND QUINONE CONJUGATES AS THERAPIES FOR CANCERS AND PROSTATE DISEASES CTSB, CTSL, CTSV HDAC1 1497/4885MAPT 3032/4885MEN1 894/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.